Effective treatment of rheumatoid arthritis (RA) has been hampered by the heterogeneity of the disease. Although early intervention can result in disease remission, it requires early diagnosis -and current diagnostic tests are not suffi ciently accurate or sensitive in the early stages of RA. As a result, RA is typically diagnosed only once damage to the joints has already begun, a time at which the window for optimal treatment may have been missed. Furthermore, a signifi cant proportion of RA patients do not respond to any given therapeutic. Research efforts are increasingly focused on discovery of biomarkers that enable early diagnosis and stratifi cation of RA, and thus the implementation of timely, targeted therapy. Biomarkers have the potential to transform the management of RA by enabling not only early diagnosis, but also assessment and prediction of disease severity, selection of therapy, and monitoring of response to therapy. In this mini review, we discuss the development of molecular biomarkers for RA.
Introduction
Rheumatoid arthritis (RA) is the most common infl ammatory joint disease of autoimmune etiology, affecting approximately 0.5% of the population. Effective treatment of RA has been impeded by a paucity of accurate diagnostic and prognostic tests, owing in part to the heterogeneity of the disease. When medical attention for arthritis symptoms is fi rst sought, the most common diagnosis is undifferentiated arthritis, i.e., arthritis that cannot be classifi ed as a specifi c disease. Patients with undifferentiated arthritis are followed over time and are not formally diagnosed with RA unless their arthritis persists for at least six weeks and they meet the current diagnostic criteria of RA [1] . RA patients are then administered therapies on a trial-and-error basis, with dose escalation, introduction of additional therapies, and change of therapy instigated if the patient does not respond satisfactorily or experiences adverse side effects. Clearly, the management of RA is currently far from optimal. It is hoped that the recent focus on biomarker discovery and development will unearth indicators of disease subtypes that can improve the diagnosis and prognosis of RA, and thus enable the implementation of targeted therapy.
Biomarkers and targeted therapy: Lessons from other diseases
Targeted therapy is needed because the uniqueness of an individual ' s genetic make-up and the heterogeneity of most diseases mean that empirically prescribed medicine is not effi cacious or safe in all patients. Targeted therapy is often referred to as personalized medicine, or the tailoring of therapeutic interventions to the individual patient; however, with a few exceptions -such as the treatment of a patient ' s cancer with a vaccine based on molecules derived from that same patient ' s tumor [2] -this is not an accurate description. Typically, targeted therapy entails matching a patient with a specifi c therapeutic that is most likely to be effective and safe based on similarities between the patient ' s ' disease signature ' and that of a cohort that has historically responded well to the therapeutic. The tools of this trade are the biomarkers, characteristics of an individual that can be objectively measured and serve as indicators of organ activity, pathogenic processes, or response to treatment. The idea is that, through the analysis of biomarkers in patient populations, a disease can be stratifi ed into distinct subsets that exhibit differential outcomes and responses to specifi c therapeutics. Thus, " stratifi ed medicine " has been proposed as a more accurate term for the majority of the current endeavors towards targeted therapy [3] .
Biomarkers come in many guises: they can be clinical, histological, or imaging parameters, as well as specifi c molecules or molecular patterns. Molecular biomarkers include genomic, proteomic, and lipidomic biomarkers. They can refl ect changes that occur early in the disease process or in the response to therapy and are thus considered one of the most valuable type of biomarker -both for discovery of disease mechanisms and therapeutic targets and for clinical decision making. In select cases, a single biomarker will suffi ce. For instance, possession of the BCR-ABL genotype indicates that a patient with chronic myeloid leukemia is likely to respond to treatment with imatinib mesylate [4] , while overexpression of the HER2 gene dictates whether a patient with breast cancer is likely to respond to trastuzumab [5] . In these examples, the biomarker is a molecule that is directly related to the pathogenesis of the disease and is targeted by the therapeutic; thus it provides a high level of predictive utility. Nevertheless, there is growing consensus that a panel of multiple biomarkersrefl ecting a so-called molecular signature -will perform better than a single biomarker in many situations, a concept that has been borne out by fi ndings in a range of diseases, including autoimmune disease, cancer, and cardiac disease [6] [7] [8] . Indeed, tests now entering the clinic are often based on profi ling of multiple biomarkers, a prime example being a prognostic test based on a 70-gene expression signature that recently obtained approval from the US Food and Drug Administration (FDA) for clinical decision making in the treatment of breast cancer (MammaPrint; Agendia, Huntington, CA, US) [9] .
Seeking biomarkers for rheumatoid arthritis
As discussed, biomarkers are integral to disease stratifi cation and hence targeted therapy. They have the potential to transform the management of RA by enabling (i) early diagnosis, (ii) assessment and prediction of disease severity, (iii) selection of therapy, and (iv) monitoring of response to therapy ( Figure) .
Early diagnosis -prevention or early intervention
Findings from the BeSt trial indicate that early therapeutic intervention can result in disease remission in a substantial proportion of RA patients [10] . In practice, however, diagnosis, and hence therapeutic intervention, is frequently delayed, resulting in increased tissue damage. Even " early ' diagnosis is currently made once erosion of cartilage and bone has already begun, a time at which the window for optimal treatment may have been missed. Biomarkers that allow earlier diagnosis of RA in patients who present with undifferentiated arthritis are needed. The most signifi cant progress in the diagnosis of RA over the last decade has been the development of assays for the detection of autoantibodies against cyclic citrullinated peptides (anti-CCP antibodies) [11] . Anti-CCP antibodies may be involved in the pathogenesis of RA [12] and, unlike the traditional RA biomarker rheumatoid factor (RF), are highly specifi c to RA [13] . However, the diagnostic sensitivity of anti-CCP antibody positivity in cohorts of early synovitis has been reported to range between 40% and 71% [14] [15] [16] . This may partly be because approximately 30% of RA patients never develop anti-CCP antibodies [17] . Thus, the search for biomarkers that provide greater sensitivity and specifi city in the diagnosis of early RA continues.
Even better than early intervention is prevention -but to prevent one must be able to predict. Although an increased risk of developing RA is indicated by several factors, including combinations of genetic and environmental factors [18] , there are no tests that identify which at-risk patients will indeed develop clinical RA. Biomarkers that can predict the onset of clinical RA during the asymptomatic phase are actively being sought. Evidence to date suggests that the presence of anti-CCP antibodies might serve as a predictor of RA onset. In retrospective analyses of blood samples collected from individuals before they developed RA, anti-CCP antibodies were found to be present up to 9 years before the onset of clinical RA and to be of value in predicting the onset of clinical RA [19, 20] . Although estimated to be 5-16 % in the general population [19, 20] , the positive predictive value (PPV) of anti-CCP antibodies is likely to be much higher in at-risk populations. Nielen et al. [19] estimate that the presence of anti-CCP antibodies in an individual with Յ 2 fi rst-degree relatives with RA would indicate a 69.4% risk of developing RA within 5 years. These retrospective fi ndings are encouraging but need to be validated in prospective longitudinal studies. The recent establishment of prospective cohort studies, e.g., SERA (Studies of the Etiology of Rheumatoid Arthritis) [21] , enrolling fi rst-degree relatives of probands with RA is anticipated to facilitate both investigation into the natural history of RA and assessment of the predictive value of anti-CCP antibodies and other biomarkers. That development of anti-CCP antibodies can precede the onset of clinical RA by several years, coupled with the cost and toxicities associated with therapeutic intervention, highlights the need for accurate biomarkers that provide temporal information indicating when an asymptomatic individual will develop RA.
Disease assessment and prognosis
The disease course in RA can range from mild and self-limiting to severe and progressive. Biological therapeutics are expensive and can have life-threatening side effects; therefore, biomarkers predictive of progression to severe RA would be useful for alerting clinicians to the need for early initiation of aggressive treatment regimens. Although it is a reliable predictor of further joint destruction in established RA, the presence of cartilage and bone erosion is not a useful prognostic biomarker in early RA, when erosions have yet to appear. Instead, the molecular harbingers of erosion must be discovered. The presence of serum RF, the presence of anti-CCP antibodies, elevations in markers of bone and cartilage turnover, and elevations in acute phase reactants have all been proposed to predict a more destructive course of RA [22] [23] [24] [25] . Nevertheless, the diagnostic sensitivity and specifi city of these biomarkers are insuffi cient to guide therapeutic decision making. A panel of multiple biomarkers is anticipated to be more accurate and informative than a single biomarker in assessing the prognosis of RA, by enabling detailed stratifi cation of the disease. Gene-expression profi les in synovial fi broblasts have been shown to defi ne molecularly distinct subsets of RA [26] ; however, such profi ling is based on an invasive procedure and is thus not feasible or justifi able in routine clinical practice. By analyzing serum samples, we demonstrated that a biomarker signature comprising elevated levels of autoantibodies could stratify early-stage RA into distinct molecular subsets that were differentially associated with clinical parameters predictive of disease severity [27] . Biomarkers need to be further developed and refi ned to attain sensitivity and specifi city suffi cient for the accurate identifi cation of individuals who will develop erosive RA, and hence the implementation of appropriate intervention.
Selection of optimal therapy
The advent of biologic therapeutics, including several different anti-TNF agents, an antibody against CD20, an IL-1 receptor antagonist, and CLTA4-Ig, has led to signifi cant advances in the treatment of RA. However, selection of therapies is still conducted on a trial-and-error basis, and less than 50% of RA patients exhibit greater than 50% improvement in their arthritis in response to any one biologic therapeutic [28] [29] [30] . Administration of a therapeutic to which a patient is not in fact responsive allows the disease to progress and places undue demand on the cost-restricted healthcare system. Therefore, biomarkers that predict response to therapy, and thereby guide the selection of appropriate therapy, are warranted.
Changes in levels of specifi c infl ammatory mediators early during treatment have been assessed as predictors of response to treatment after 3 months [31] . Although such molecular changes may be useful as pharmacodynamic biomarkers for the monitoring of response to therapy, biomarkers at baseline (i.e., before treatment is commenced) are ultimately needed for the prediction of response to therapy. RF and anti-CCP-antibody status at baseline is associated with response to anti-TNF agents, but it accounts for only a small proportion of the variance in response and cannot predict the response [32, 33] . Gene-expression profi les in white blood cells [34] or whole blood [35] , and cytokine levels in whole blood [36] , have been shown to predict response to anti-TNF agents in single cohorts. While informative, molecular signatures identifi ed in single cohorts in some cases cannot be replicated in independent cohorts [37] . Using blood samples from three ethnically distinct cohorts, we identifi ed a biomarker signature comprising 13 autoantibodies and 11 cytokines that could distinguish between RA patients who will respond to anti-TNF treatment and those who will not [38] . The PPV of this fi rstgeneration signature ranged from 58% in the Japanese cohort to 71% in the North American cohort, but could potentially be improved by incorporation of additional proteomic, genetic, clinical or imaging-based biomarkers. Because both autoantibodies and cytokines play a key role in the pathogenesis of RA [12, 39] , biomarker profi les that include these parameters are anticipated to enable stratifi cation of disease.
In addition to biomarkers predictive of drug response, biomarkers predictive of drug toxicity are being developed, in the hope of improving the safety of RA therapy. For instance, genotypes of folatedependent enzymes have been proposed to be of value in predicting which RA patients will develop adverse side effects following treatment with the antifolate agent methotrexate [40] . Biomarkers predictive of toxicity due to biologic agents have yet to be reported.
Genomic vs proteomic biomarkers
Both genomic and proteomic biomarkers are under investigation as potential tools for clinical decision making in RA. There are pros and cons associated with both. Genetic biomarkers are incontrovertibly valuable indicators of susceptibility to the development of RA. Most prominent of such genetic biomarkers is the HLA-DR shared epitope, which, in combination with cigarette smoking, is known to be a risk factor for the development of anti-CCPantibody-positive RA [18] . Additional genetic biomarkers of RA susceptibility continue to be uncovered by ongoing genome-wide association studies [41] . The value of genetic biomarkers in prognosis of disease outcome or of response to therapy is less clear [33, 42] . Gene-expression profi les, on the other hand, may serve as prognostic biomarkers in RA [26, [34] [35] , though preliminary fi ndings remain to be validated. Nevertheless, biomarker discovery based on genotyping or transcriptional profi ling has certain limitations. Changes in genetic sequence do not always translate to changes in gene expression or protein activity, and the concordance between levels of gene transcripts and levels of the proteins they encode is low. Furthermore, profi ling of gene transcripts does not take into account posttranslational modifi cations, which can play an important role in disease pathogenesis. This is particularly true of autoimmune diseases such as RA, in which autoantibody production and the formation of neoepitopes through posttranslational modifi cation play pivotal roles in disease pathogenesis [43] . For these reasons, many researchers are now focusing their efforts on the discovery of proteomic biomarkers, though proteomic-biomarker discovery has its share of limitations, including biased screening and technical challenges [37] .
Stratifi ed medicine: A win-win situation
Diagnostic and prognostic biomarkers have the potential to benefi t patients immensely, by enabling precise and timely diagnosis of disease and selection of the most appropriate therapy. But the patients are not the only ones set to benefi t -stratifi ed medicine is appealing to the clinical trialists and drug developers, too. By enriching cohorts in clinical trials with patients likely to respond to a therapeutic, prognostic biomarkers can reduce the trial size required to determine therapeutic effi cacy [3] . Moreover, they could potentially allow older drugs that were deemed unsafe or ineffective to be reassessed in discreet patient subsets. Pharmacodynamic biomarkers can be used to monitor the effi cacy and safety of an investigational drug and can accelerate early-stage clinical trials in which one of the major objectives is to defi ne the range of active drug doses. While efforts aimed at biomarker discovery are burgeoning, the use of biomarkers in clinical trials and clinical practice is in its infancy. Replication and validation of biomarkers in prospective clinical trials will be of paramount importance, as will proof of their impact on management of disease and utilization of health-care resources. We anticipate that, as additional therapeutics and enabling technologies become available, stratifi ed medicine based on biomarkers will increasingly take a leading role in the practice of medicine.
